171 related articles for article (PubMed ID: 28163023)
21. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
22. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.
Bousette N; Pottinger J; Ramli W; Ohlstein EH; Dhanak D; Douglas SA; Giaid A
Peptides; 2006 Nov; 27(11):2919-26. PubMed ID: 16919371
[TBL] [Abstract][Full Text] [Related]
23. The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure.
Nishi M; Tagawa H; Ueno M; Marumoto S; Nagayama T
Heliyon; 2020 Feb; 6(2):e03352. PubMed ID: 32055741
[TBL] [Abstract][Full Text] [Related]
24. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
Zhang YG; Li YG; Liu BG; Wei RH; Wang DM; Tan XR; Bu DF; Pang YZ; Tang CS
Acta Pharmacol Sin; 2007 Jan; 28(1):36-43. PubMed ID: 17184580
[TBL] [Abstract][Full Text] [Related]
25. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Yamazaki T; Yamashita N; Izumi Y; Nakamura Y; Shiota M; Hanatani A; Shimada K; Muro T; Iwao H; Yoshiyama M
Hypertens Res; 2012 Jan; 35(1):34-40. PubMed ID: 21866107
[TBL] [Abstract][Full Text] [Related]
26. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice.
Suzuki K; Satoh K; Ikeda S; Sunamura S; Otsuki T; Satoh T; Kikuchi N; Omura J; Kurosawa R; Nogi M; Numano K; Sugimura K; Aoki T; Tatebe S; Miyata S; Mukherjee R; Spinale FG; Kadomatsu K; Shimokawa H
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):636-46. PubMed ID: 26916734
[TBL] [Abstract][Full Text] [Related]
27. Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats.
Hong Y; Hui SC; Chan TY; Hou JY
Am J Chin Med; 2002; 30(4):589-99. PubMed ID: 12568286
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
[TBL] [Abstract][Full Text] [Related]
29. A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure.
Aubdool AA; Thakore P; Argunhan F; Smillie SJ; Schnelle M; Srivastava S; Alawi KM; Wilde E; Mitchell J; Farrell-Dillon K; Richards DA; Maltese G; Siow RC; Nandi M; Clark JE; Shah AM; Sams A; Brain SD
Circulation; 2017 Jul; 136(4):367-383. PubMed ID: 28446517
[TBL] [Abstract][Full Text] [Related]
30. Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis.
Xu Q; Lekgabe ED; Gao XM; Ming Z; Tregear GW; Dart AM; Bathgate RA; Samuel CS; Du XJ
Endocrinology; 2008 Feb; 149(2):476-82. PubMed ID: 17991721
[TBL] [Abstract][Full Text] [Related]
31. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
32. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload.
Matsusaka H; Ide T; Matsushima S; Ikeuchi M; Kubota T; Sunagawa K; Kinugawa S; Tsutsui H
Hypertension; 2006 Apr; 47(4):711-7. PubMed ID: 16505197
[TBL] [Abstract][Full Text] [Related]
33. Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling.
Zong J; Zhang DP; Zhou H; Bian ZY; Deng W; Dai J; Yuan Y; Gan HW; Guo HP; Tang QZ
J Cell Biochem; 2013 May; 114(5):1058-65. PubMed ID: 23225340
[TBL] [Abstract][Full Text] [Related]
34. The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats.
Pelzer T; Jazbutyte V; Hu K; Segerer S; Nahrendorf M; Nordbeck P; Bonz AW; Muck J; Fritzemeier KH; Hegele-Hartung C; Ertl G; Neyses L
Cardiovasc Res; 2005 Sep; 67(4):604-12. PubMed ID: 15950203
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
[TBL] [Abstract][Full Text] [Related]
36. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
Chang SA; Kim YJ; Lee HW; Kim DH; Kim HK; Chang HJ; Sohn DW; Oh BH; Park YB
Hypertension; 2009 Sep; 54(3):591-7. PubMed ID: 19564547
[TBL] [Abstract][Full Text] [Related]
37. Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities.
Ozoux ML; Briand V; Pelat M; Barbe F; Schaeffer P; Beauverger P; Poirier B; Guillon JM; Petit F; Altenburger JM; Bidouard JP; Janiak P
J Pharmacol Exp Ther; 2020 Jul; 374(1):24-37. PubMed ID: 32332113
[TBL] [Abstract][Full Text] [Related]
38. Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Szabó Z; Magga J; Alakoski T; Ulvila J; Piuhola J; Vainio L; Kivirikko KI; Vuolteenaho O; Ruskoaho H; Lipson KE; Signore P; Kerkelä R
Hypertension; 2014 Jun; 63(6):1235-40. PubMed ID: 24688123
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy.
Hoffmann S; Krause T; van Geel PP; Willenbrock R; Pagel I; Pinto YM; Buikema H; van Gilst WH; Lindschau C; Paul M; Inagami T; Ganten D; Urata H
J Mol Med (Berl); 2001 Oct; 79(10):601-8. PubMed ID: 11692158
[TBL] [Abstract][Full Text] [Related]
40. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure.
Zhang L; Liu M; Jiang H; Yu Y; Yu P; Tong R; Wu J; Zhang S; Yao K; Zou Y; Ge J
J Cell Mol Med; 2016 Mar; 20(3):459-70. PubMed ID: 26647902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
